Only 192 applications approved under RPTUAS to upgrade existing units to revised Schedule M standards: Gireesh Babu, New Delhi Thursday, December 11, 2025, 08:00 Hrs [IST] Even as ...
RGUHS fee hike for pharmacy, medical & nursing education undermines State’s health education ecosystem: Nandita Vijayasimha, Bengaluru Thursday, December 11, 2025, 08:00 Hrs [IS ...
Indian govt initiates discussion to fast-track approval for pharmaceuticals in Taiwan: Shardul Nautiyal, Mumbai Thursday, December 11, 2025, 08:00 Hrs [IST] The Government of Indi ...
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has sought pharma industry inputs to usher in industry engagement towards strengthening India-United Kingdom (UK) Comprehensive ...
AICDF pushes for prosecution of pharma houses for decade-long non-compliance: Peethaambaran Kunnathoor, Chennai Thursday, December 11, 2025, 08:00 Hrs [IST] The All India Chemists ...
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study: Basel Wednesday, December 10, 2025, 18:00 Hrs [IST] Roch ...
Kiran Mazumdar-Shaw honoured with ‘USC Business Management Award’ for her contributions in global healthcare and biotechnology: Our Bureau, Bengaluru Wednesday, December 10, 2 ...
EpiVax and US FDA scientists publish new insights on immunogenicity risks of peptide-related impurities in generic teriparatide: Providence, Rhode Island Wednesday, December 10, 2 ...
Japan’s MHLW grants Pioneering Regenerative Medical Product Designation to AskBio’s AB-1005 and AB-1002: Berlin, Germany Wednesday, December 10, 2025, 12:00 Hrs [IST] AskBio I ...
Zydus and Formycon partner for licensing and supply of biosimilar to Keytruda in US and Canada: Our Bureau, Mumbai Wednesday, December 10, 2025, 15:20 Hrs [IST] Zydus Lifesciences ...
Roche introduces new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark: Basel Wednesday, December 10, 2025, 15:00 Hrs ...
Consistently high efficacy was seen across subgroups with ORR of 96%-100% and three-year ongoing response rates of 60%-83%, including in patients with high-risk characteristics (progression of disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results